New study aims to find safer heart failure treatment for kidney patients
NCT ID NCT07523867
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two drugs, finerenone and spironolactone, in 60 adults with heart failure and diabetic kidney disease who are at high risk for high potassium levels (hyperkalemia). Participants will receive either finerenone daily or spironolactone every other day, plus standard care, and be monitored for 4 weeks. The goal is to see which drug is safer by tracking potassium levels and any need to stop or adjust treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••